Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us

    News: Cancer Research

    Endowed fellowships help create personal connections

    Monday, May 16th, 2016

    When former Nashvillian Carol O’Hare speaks about a specific group of physicians at Vanderbilt-Ingram Cancer Center (VICC), her voice softens, and she refers to them affectionately as “my fellows.” O’Hare, a 19-year cancer survivor who received life-saving treatment at VICC and whose late husband was also treated for cancer here, decided to support oncology research […]

    Improving natural killer cancer therapy

    Friday, May 6th, 2016

    Natural Killer (NK) cells are a type of white blood cell that specifically recognize and destroy tumor cells. For this reason, NK cell transfer therapy is a promising cancer treatment. Expansion and persistence of donor NK cells correlates with tumor clearance, suggesting that therapeutic efficacy can be enhanced by augmenting NK cell survival. Now, Whitney […]

    Current cancer drug discovery method flawed: VUMC study

    Friday, May 6th, 2016

    The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods. The findings cast doubt on methods used by the entire scientific enterprise and pharmaceutical industry to discover new cancer drugs. “More than 90 percent of candidate cancer drugs fail in late-stage clinical […]

    Zanic’s research recognized with 2016 Searle Scholarship

    Friday, April 29th, 2016

    An expert in the dynamic behavior of the microtubule cytoskeleton at Vanderbilt University is among 15 scientists in the chemical and biological sciences nationwide who have been named 2016 Searle Scholars. Marija Zanic, Ph.D., assistant professor of Cell and Developmental Biology and of Chemical and Biomolecular Engineering, will receive $300,000 in flexible funding from the […]

    An Argonaute’s voyage to cancer

    Friday, April 29th, 2016

    Mutations in the KRAS gene, which codes for a protein involved in normal cell signaling, promote the development of colorectal and other cancers. One mechanism by which activated KRAS may influence the phenotype of neighboring cells is by regulating the packaging of tiny RNAs called microRNAs (miRNAs) in small, bubble-like vesicles called exosomes. When delivered […]

    Study explores how some breast cancers resist treatment

    Thursday, April 21st, 2016

    A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies. The new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators has identified gene alterations […]

    VICC’s Annual Scientific Retreat set for May 6

    Thursday, April 21st, 2016

    Scientists, physicians, staff members and patients interested in the latest in cancer research are invited to attend the Vanderbilt-Ingram Cancer Center (VICC) Annual Scientific Retreat to be held Friday, May 6, 8 a.m. – 3 p.m., at the Vanderbilt University Student Life Center. This year’s theme, “At the Crossroads: Metabolism and Oncogenic Signaling,” will explore […]

    Mechanism of a DNA repair protein

    Friday, April 15th, 2016

    A DNA replication machine acts at a “replication fork” to unzip and copy DNA. But many obstacles, such as damaged DNA and unusual DNA structures, can stall replication forks with severe consequences, such as mutation and DNA rearrangements that cause cancer. Replication stress response proteins such as ZRANB3 minimize inaccuracies in DNA copying by stabilizing […]

    Switching breast cancer off

    Thursday, April 14th, 2016

    Receptor tyrosine kinases (RTKs) – key regulators of cell signaling pathways – are commonly implicated in the proliferation of malignant tumors. The EPHA2 RTK is overexpressed in aggressive forms of breast cancer, and this overexpression correlates with poor patient outcomes. EPHA2 is believed to operate somewhat like a switch: when its ligand, ephrin-A1, is present, […]

    Pietenpol named Executive Vice President for Research

    Thursday, April 14th, 2016

    Jennifer Pietenpol, Ph.D., director of the Vanderbilt-Ingram Cancer Center, B.F. Byrd Jr. Professor of Molecular Oncology and Professor of Biochemistry, Cancer Biology and Otolaryngology, has been named Executive Vice President for Research at Vanderbilt University Medical Center (VUMC). Her appointment is effective May 1. Pietenpol will assume this new role while continuing to serve as […]

    Next Page »« Previous Page

    E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us